Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?
07:38am, Tuesday, 18'th Apr 2023
Celldex (CLDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
09:01am, Wednesday, 29'th Mar 2023
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Infla
Celldex: Long List Of Failures, High Valuation, But Good Data Recently
05:10am, Monday, 20'th Feb 2023
Celldex has failed too many times to inspire confidence. The company's current valuation is also quite high.
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
07:00am, Wednesday, 15'th Feb 2023
HAMPTON, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chat at the SVB Securities Global Biopharma Confe
Celldex to Participate in Upcoming November Investor Conferences
04:01pm, Thursday, 10'th Nov 2022
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in No
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 09'th Nov 2022
Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates
09:25pm, Monday, 08'th Aug 2022 Zacks Investment Research
Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
09:15pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review
04:06pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.
Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
03:32pm, Thursday, 14'th Jul 2022
Proof of concept has been established in using Barzolvolimab in treating Chronic spontaneous urticaria and Chronic inducible urticaria patients in phase 1b studies. One phase 2 study with Barzolvolima
Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?
01:55pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?
11:40am, Wednesday, 06'th Jul 2022
The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?
11:20am, Wednesday, 06'th Jul 2022 Zacks Investment Research
Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?
08:35am, Wednesday, 06'th Jul 2022
Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
